{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"66"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"119"}],"units":"Participants"}],"description":"All randomized subjects with at least 1 evaluable postrandomization bone marrow assessment performed on or after Day 14 after the last induction were assessed for MLFS.","groups":[{"description":"Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with CPX-351. The number of inductions and consolidations a subject received depended on response.","id":"OG000","title":"Arm A (CPX-351)"},{"description":"Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with cytarabine and daunorubicin given as a 7 + 3, or 5 days of continuous infusion of cytarabine and 2 days of daunorubicin (5+2, second induction, consolidation courses) therapy. The number of inductions and consolidations a subject received depended on response.","id":"OG001","title":"Arm B (7+3)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Intent-to-Treat (ITT) Population: All participants randomized in the study.","reportingStatus":"POSTED","timeFrame":"Day 14","title":"Rate of Achieving Morphologic Leukemia-free State","type":"SECONDARY","unitOfMeasure":"Participants"}